Recombinant anti-CD20 humanized monoclonal antibody (Shanghai Jiaolian Drug) in Myasthenia Gravis: NCT06447597 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 28 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 2/3
Clinical phase
Recruiting
Recruitment status
104
Planned enrollment
2026-12-30
Primary-completion proxy
Executive view
NCT06447597 evaluates Recombinant anti-CD20 humanized monoclonal antibody (Shanghai Jiaolian Drug) in Myasthenia Gravis. The disclosed sponsor is Shanghai Jiaolian Drug Development Co. Ltd., the design is Interventional, and the geographic footprint is China. The first listed primary endpoint is Proportion of subjects：MG-ADL（Myasthenia gravis-activities of daily living profile） decreased by ≥2, assessed over Approximately 16 weeks.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT06447597 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Myasthenia Gravis landscape. Drug & Asset MCP drug_fetch was queried for Recombinant anti-CD20 humanized monoclonal antibody (Shanghai Jiaolian Drug), while Company & Deal Intelligence MCP organization_fetch was queried for Shanghai Jiaolian Drug Development Co. Ltd..
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT06447597 | Recombinant anti-CD20 humanized monoclonal antibody (Shanghai Jiaolian Drug) | Phase 2/3 / Recruiting | Shanghai Jiaolian Drug Development Co. Ltd. | China | Proportion of subjects：MG-ADL（Myasthenia gravis-activities of daily living profile） decreased by ≥2 Approximately 16 weeks | 2026-12-30 |
| NCT06587867 | Efgartigimod Alfa | Phase 3 / Unknown status | University Health Network | Canada | Total Myasthenia Gravis Impairment Index (MGII) score through study completion for 42 weeks | 2025-05-01 |
| NCT06558279 | Efgartigimod/Hyaluronidase | Phase 3 / Active, not recruiting | argenx SE | Cyprus, Czechia, United States, Japan, United Kingdom, United Arab Emirates, Portugal, Spain, Greece, Canada, Sweden, South Korea, Netherlands, Austria, Belgium, China, Finland, Poland, Denmark, Italy, Serbia, France, Australia, Germany | MGII (PRO) ocular score change from baseline to day 29 in part A Up to 29 days | 2026-01-12 |
| NCT06548620 | RD-06-04 | Early Phase 1 / Withdrawn | Nanjing Bioheng Biotech Co., Ltd. | China | Incidence of treatment-emergent adverse events, serious adverse events and incidence of adverse events of special inte… up to 2 years | 2026-08-31 |
| NCT06540144 | Rozanolixizumab | Phase 3 / Enrolling by invitation | UCB Biopharma SRL | Japan, Turkey, Taiwan Province, Poland, Italy | Occurrence of serious Treatment-Emergent Adverse Events (TEAEs) up to the End of Study (EOS) Visit From Baseline up to the EOS Visit (up to 52 weeks) | 2027-08-17 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT06447597 is a Phase 2/3, recruiting study with 104 planned participants. Allocation is Randomized, masking is Double, and the intervention model is Parallel Assignment.
The primary endpoint is “Proportion of subjects：MG-ADL（Myasthenia gravis-activities of daily living profile） decreased by ≥2” over “Approximately 16 weeks.” The retrieved endpoint description is: Proportion of subjects：MG-ADL decreased by ≥2.
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 104 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Myasthenia Gravis. These records do not establish direct evidence for NCT06447597 unless the registration number matches.
Management of Exacerbations and Rescue Therapy in the Phase 3 Myasthenia Gravis Inebilizumab Trial
Phase 3; n=238; exacerbation(26-week): HR = 0.41(95.0% CI, 0.24 - 0.7); exacerbation(26-week): HR = 0.41(95.0% CI, 0.24 - 0.7) Source: https://pubmed.ncbi.nlm.nih.gov/42573995/
A Randomized, Double-Blinded, Placebo-Controlled, Phase 3, Parallel-Group Design Study Evaluating the Efficacy and Safety of Efgartigimod IV in Adult Participants With Acetylcholi…
Phase 3; n=119; MG-ADL Total Score Change From Baseline(Least Squares Mean) = -1.90 points on a scale (90% Confidence Interval, -2.51 to -1.28); MG-ADL Total Score Change From Baseline(Least Squares Mean) = -3.35 points on a scale (90% Confidence Interval, -3.98 to -2.72) Source: https://clinicaltrials.gov/ct2/show/results/NCT06298552
Assessment of sustained health- related quality of life in Phase 3 Vivacity-MG3 Trial of Nipocalimab versus Placebo in Generalized Myasthenia Gravis
Phase 3; n=129; EQ-5D-VAS(24-week) = 37.1 % ; EQ-5D-VAS(24-week) = 55.2 % Source: https://onlinelibrary-wiley-com.sutd.idm.oclc.org/journal/14681331
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
Recombinant anti-CD20 humanized monoclonal antibody (Shanghai Jiaolian Drug) is indexed as Monoclonal antibody with CD20 biology and a global stage of Phase 2/3. The asset profile lists Shanghai Jiaolian Drug Development Co. Ltd. as an originator or developer.
Shanghai Jiaolian Drug Development Co. Ltd. is indexed in China. Develops pharmaceutical products The record lists 5 development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Recombinant anti-CD20 humanized monoclonal antibody (Shanghai Jiaolian Drug) is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT06447597
Protocol source: https://clinicaltrials.gov/study/NCT06447597
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 28 September 2026.
Recombinant anti-CD20 humanized monoclonal antibody (Shanghai Jiaolian Drug) in Myasthenia Gravis is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Proportion of subjects：MG-ADL（Myasthenia gravis-activities of daily living profile） decreased by ≥2 and 2026-12-30 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
